Tiger Brokers

HK StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

SINO BIOPHARM

3.950
+0.0601.54%
Volume:146.22M
Turnover:582.68M
Market Cap:74.14B
PE:19.39
High:4.090
Open:3.980
Low:3.910
Close:3.890
Loading ...
OverviewCompanyNewsFilings

Sino Biopharmaceutical Gets FDA Nod to Market Cancer Drug

MT Newswires Live
·
25 Apr

Sino Biopharmaceutical - Approval for Marketing of Penpulimab Injection by US FDA

THOMSON REUTERS
·
25 Apr

Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial

MT Newswires Live
·
10 Apr

BRIEF-Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA

Reuters
·
09 Apr

Sino Biopharmaceutical - Tqb3019 (Btk Protac) Approved for Clinical Trial by Nmpa

THOMSON REUTERS
·
09 Apr

Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China

MT Newswires Live
·
04 Apr

BRIEF-Sino Biopharmaceutical Says Positive Results On Phase 3 Study Of Culmerciclib In Combination With Fulvestrant

Reuters
·
24 Mar

Sino Biopharmaceutical - Positive Results on Phase Iii Study of Culmerciclib in Combination With Fulvestrant

THOMSON REUTERS
·
24 Mar

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$5.52 From HK$6.42, Keeps at Buy

MT Newswires Live
·
21 Mar

Sino Biopharmaceutical's 2024 Attributable Profit Jumps 50%

MT Newswires Live
·
20 Mar

BRIEF-Sino Biopharmaceutical Recommends Payment Of Final Dividend Of HK4 Cents Per Share

Reuters
·
20 Mar

Sino Biopharmaceutical - Recommended Payment of a Final Dividend of HK4 Cents per Share for Year

THOMSON REUTERS
·
20 Mar

Sino Biopharmaceutical - Recommended Payment of a Final Dividend of HK4 Cents per Share

THOMSON REUTERS
·
20 Mar

Sino Biopharmaceutical - FY Revenue RMB28.87 Bln

THOMSON REUTERS
·
20 Mar

Sino Biopharmaceutical's (HKG:1177) earnings have declined over five years, contributing to shareholders 43% loss

Simply Wall St.
·
13 Mar

Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months

MT Newswires Live
·
11 Mar

BRIEF-Sino Biopharmaceutical Enters Exclusive Cooperation Agreement With Delova Biotech For QP001

Reuters
·
06 Mar

Sino Biopharmaceutical - Entering Into an Exclusive Cooperation Agreement With Delova Biotech for Qp001

THOMSON REUTERS
·
06 Mar

Sino Biopharmaceutical - Expects That Product Will Be Approved by National Medical Products Administration of China for Marketing in Near Future

THOMSON REUTERS
·
06 Mar

BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences

Reuters
·
27 Feb
More